Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02778399 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
A Phase 2 study, sponsored by ObsEva.
- Completed
- Registry status
- Phase 2
- Development phase
- 328
- Enrollment target
NCT02778399: Completed Phase 2 study, sponsored by ObsEva.
NCT02778399 is a Phase 2 study that has completed, run by ObsEva. The registered enrollment target is 328 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (147% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02778399, a Phase 2 study, has completed, sponsored by ObsEva.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 328 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the efficacy and safety of a range of oral doses of OBE2109 versus placebo, in reducing endometriosis associated pain.
Primary Outcome
The primary efficacy endpoint of the study was a response at Week 12, with response defined as a reduction of 30% or greater from baseline in the mean overall pelvic pain score, defined as the mean of daily pain scores reported in electronic diary during the preceding 28 days (4-week period), assessed on a Verbal Rating Scale for pelvic pain of 0 (no pain) to 3 (severe pain). The baseline mean score was calculated as the mean of daily scores recorded in electronic diary over the two complete men
Interventions
- DRUG Placebo
- DRUG OBE2109
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 328 participants |
| Start Date | 2016-07 |
| Est. Completion | 2019-07-01 |
| Phase | Phase 2 |
What the finished NCT02778399 record still lists
NCT02778399 is an interventional study that assigns participants to a tested intervention. The registered 328 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (147% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02778399 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02778399 about?
NCT02778399 is a clinical study titled "A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis". The primary objective of this study is to assess the efficacy and safety of a range of oral doses of OBE2109 versus placebo, in reducing endometriosis associated pain.
What is the current status of trial NCT02778399?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 328 participants. The study started on 2016-07. Estimated completion is 2019-07-01.
What interventions are being tested in trial NCT02778399?
The interventions under investigation include: Placebo (DRUG), OBE2109 (DRUG).
Who is sponsoring clinical trial NCT02778399?
This trial is sponsored by ObsEva, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02778399's enrollment target sits among peer trials
328 146th of 2000 higher than 1,855 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05156983 · 328 participants · Phase 3
A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery
- NCT05380401 · 328 participants · NA
Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants
- NCT05548413 · 328 participants · NA
Improving Medication Adherence Using Family-focused and Literacy-sensitive Strategies
- NCT06393725 · 328 participants · NA
Synchronous vs Asynchronous Remotely Delivered Lifestyle Interventions
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia